Acasti Pharma (Nasdaq:ACST) - Stock Price, News & Analysis

ACST Stock Overview

Acasti Pharma Inc. se dedica al desarrollo y comercialización de productos farmacéuticos para enfermedades raras y huérfanas en Canadá.

About the company

ACST fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas se han diluido en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización bursátil significativa ($21M)

Acasti Pharma Inc. Competitors

VYNE Therapeutics

NasdaqCM:VYNE

US$43.7m

Kiora Pharmaceuticals

NasdaqCM:KPRX

US$15.5m

Cocrystal Pharma

NasdaqCM:COCP

US$14.6m

Talphera

NasdaqGM:TLPH

US$17.1m

Price History & Performance

Summary of all time highs, changes and price drops for Acasti Pharma
Historical stock prices
Current Share Price	US$3.40
52 Week High	US$3.84
52 Week Low	US$1.72
Beta	1.53
1 Month Change	-0.15%
3 Month Change	18.47%
1 Year Change	29.02%
3 Year Change	-87.23%
5 Year Change	-92.60%
Change since IPO	-99.42%

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Nov 14

Recent updates

Shareholder Returns

	ACST	US Pharmaceuticals	US Market
7D	-0.7%	-1.4%	-0.8%
1Y	29.0%	17.6%	26.6%

Rentabilidad frente al sector: ACST superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 22.5% el año pasado.

Rentabilidad vs. Mercado: ACST superó al mercado US, que obtuvo un rendimiento del 25.8% el año pasado.

Price Volatility

Is ACST's price volatile compared to industry and market?
ACST volatility
ACST Average Weekly Movement	9.7%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ACSTha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ACST (10%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Prashant Kohli	https://www.acastipharma.com

Acasti Pharma Inc. se dedica al desarrollo y comercialización de productos farmacéuticos para enfermedades raras y huérfanas en Canadá. El principal producto candidato de la empresa es el GTX-104, una infusión intravenosa para tratar la hemorragia subaracnoidea. También desarrolla GTX-102, un aerosol oral mucoso para el tratamiento de la ataxia-telangiectasia; y GTX-101, un aerosol tópico bioadhesivo de bupivacaína para la neuralgia postherpética.

Acasti Pharma Inc. Fundamentals Summary

How do Acasti Pharma's earnings and revenue compare to its market cap?
ACST fundamental statistics
Market cap	US$31.77m
Earnings (TTM)	-US$38.77m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is ACST overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACST income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$38.77m
Earnings	-US$38.77m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ACST perform over the long term?

See historical performance and comparison

ACST Stock Overview

Rewards

Risk Analysis

Acasti Pharma Inc. Competitors

NasdaqCM:VYNE

US$43.7m

NasdaqCM:KPRX

US$15.5m

NasdaqCM:COCP

US$14.6m

NasdaqGM:TLPH

US$17.1m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Recent updates

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Forecast to breakeven in 2024

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Forecast to breakeven in 2024

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Acasti inks deal for Grace Therapeutics, shares surge

Earnings miss expectations

New 90-day high: US$0.90

New 90-day high: US$0.57

New 90-day high: US$0.43

Acasti Pharma issues clarification on trading activity

New 90-day high: US$0.29

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma EPS in-line

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - US$0.24

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Shareholder Returns

Price Volatility

About the Company

Acasti Pharma Inc. Fundamentals Summary

0.0x

-0.8x